Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2022 Sep 15;60(3):2102865.
doi: 10.1183/13993003.02865-2021. Print 2022 Sep.

The burden of asthma, hay fever and eczema in adults in 17 countries: GAN Phase I study

Kevin Mortimer  1   2 , Maia Lesosky  3   4 , Luis García-Marcos  5   6 , M Innes Asher  7 , Neil Pearce  8 , Eamon Ellwood  7 , Karen Bissell  9 , Asma El Sony  10 , Philippa Ellwood  7 , Guy B Marks  11 , Antonela Martínez-Torres  12   13 , Eva Morales  14 , Virginia Perez-Fernandez  15 , Steven Robertson  8 , Charlotte E Rutter  8 , Richard J Silverwood  8   16 , David P Strachan  17 , Chen-Yuan Chiang  18   19   20 ; Global Asthma Network Phase I Study Group
Affiliations
Clinical Trial

The burden of asthma, hay fever and eczema in adults in 17 countries: GAN Phase I study

Kevin Mortimer et al. Eur Respir J. .

Abstract

Aims: Asthma, hay fever and eczema are three common chronic conditions. There have been no recent multi-country data on the burden of these three conditions in adults; the aims of this study are to fill this evidence gap.

Methods: The Global Asthma Network Phase I is a multi-country cross-sectional population-based study using the same core methodology as the International Study of Asthma and Allergies in Childhood Phase III. It provides data on the burden of asthma, hay fever and eczema in children and adolescents, and, for the first time, in their parents/guardians.

Results: Data were available from 193 912 adults (104 061 female; mean±sd age 38±7.5 years) in 43 centres in 17 countries. The overall prevalence (range) of symptoms was 6.6% (0.9-32.7%) for current wheeze, 4.4% (0.9-29.0%) for asthma ever, 14.4% (2.8-45.7%) for hay fever ever and 9.9% (1.6-29.5%) for eczema ever. Centre prevalence varied considerably both between countries and within countries. There was a moderate correlation between hay fever ever and asthma ever, and between eczema ever and hay fever ever at the centre level. There were moderate to strong correlations between indicators of the burden of disease reported in adults and the two younger age groups.

Conclusion: We found evidence for a substantial burden of asthma, hay fever ever and eczema ever in the countries examined, highlighting the major public health importance of these diseases. Prevention strategies and equitable access to effective and affordable treatments for these three conditions would help mitigate the avoidable morbidity they cause.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: The authors declare that they have no conflict of interest.

Figures

FIGURE 1
FIGURE 1
Map of the prevalence of asthma ever. The symbols indicate prevalence values of <5% (blue squares), 5 to <10% (green circles), 10 to <20% (yellow diamonds) and ≥20% (red stars).
FIGURE 2
FIGURE 2
Map of the prevalence of current wheeze. The symbols indicate prevalence values of <5% (blue squares), 5 to <10% (green circles), 10 to <20% (yellow diamonds) and ≥20% (red stars).
FIGURE 3
FIGURE 3
Map of the prevalence of hay fever ever. The symbols indicate prevalence values of <5% (blue squares), 5 to <10% (green circles), 10 to <20% (yellow diamonds) and ≥20% (red stars).
FIGURE 4
FIGURE 4
Map of the prevalence of eczema ever. The symbols indicate prevalence values of <5% (blue squares), 5 to <10% (green circles), 10 to <20% (yellow diamonds) and ≥20% (red stars).
FIGURE 5
FIGURE 5
Rank correlation values and scatter plots of prevalence of the three conditions at the centre level. The dashed line is the identity line. Rank correlation coefficient (Rho) and 95% CI are shown in each graph.
See this image and copyright information in PMC

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Meghji J, Mortimer K, Agusti A, et al. Improving lung health in low-income and middle-income countries: from challenges to solutions. Lancet 2021; 397: 928–940. doi: 10.1016/S0140-6736(21)00458-X - DOI - PubMed
    1. Vos T, Lim SS, Abbafati C, et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 2020; 396: 1204–1222. doi: 10.1016/S0140-6736(20)30925-9 - DOI - PMC - PubMed
    1. Mortier K, Reddel HK, Pitrez PM, et al. Asthma management in low- and middle-income countries: case for change. Eur Resp J 2022; 60: 2103179. - PMC - PubMed
    1. Asher I, Bissell K, Chiang C-Y, et al. Calling time on asthma deaths in tropical regions: how much longer must people wait for essential medicines? Lancet Respir Med 2019; 7: 13–15. doi: 10.1016/S2213-2600(18)30513-7 - DOI - PubMed
    1. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee . Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. Lancet 1998; 351: 1225–1232. doi: 10.1016/S0140-6736(97)07302-9 - DOI - PubMed

Publication types